“…A recent systematic review of coiling literature reported a rate of 18% of such outcomes. 1 In an effort to improve long-term occlusion rates, a number of "modified," second-generation coil types have been developed and marketed. Numerous single-center case series have been published regarding outcomes for each of these second-generation coil types, including Matrix (Boston Scientific, Natick, Massachusetts), [2][3][4] HydroCoil (MicroVention, Tustin, California), [5][6][7] and Cerecyte coils (Codman Neurovascular, Raynham, Massachusetts).…”